---
title: AVIM Therapy Patent Portfolio Reaches New Milestone
description: This week, Orchestra BioMed announced that its global intellectual property (IP) estate for AVIM™ therapy has reached 137 issued patents, reinforcing the company’s dominant IP protection for its unique device-based treatment for hypertension and heart failure.
---

[Content Hub ](https://www.orchestrabiomed.com/hub)

# [AVIM Therapy Patent Portfolio Reaches New Milestone](https://www.orchestrabiomed.com/hub/avim-therapy-patent-portfolio-reaches-new-milestone)

 Written by [Orchestra BioMed](https://www.orchestrabiomed.com/hub/author/orchestra-biomed) | May 9, 2025 11:00:00 AM

Blog Post - AVIM Therapy Patent Portfolio Reaches New Milestone

**OBIO | AVIM Patent Portfolio Reaches New Milestone**

#### Fellow Shareholders:

This week, Orchestra BioMed [announced that its global intellectual property (IP) estate for AVIM™ therapy has reached **137 issued patents**](https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomeds-avim-therapy-global-intellectual-property), reinforcing the company’s dominant IP protection for its unique device-based treatment for hypertension and heart failure.

This announcement reflects a year of focused execution, during which OBIO secured **10 new patents related to hypertension** and unveiled a **17-patent portfolio covering heart failure applications**.

In total, OBIO’s AVIM Therapy issued patent portfolio comprises over 2,100 individual proprietary claims.

We’ve summarized the key evolution of our hypertension IP portfolio since last April’s announcement in the chart below:

#### ***"Building a Global Hypertension IP Fortress: AVIM Patent Growth Year-over-Year"***

 

| **Category** | **April 2024** | **May 2025** | **YoY Change** |
| --- | --- | --- | --- |
| **Total Issued Patents** | 110 | 120 | ▲ +10 |
| - U.S. Patents | 37 | 46 | ▲ +9 |
| - International Patents | 73 | 91 | ▲ +18 |

 

Together, these milestones underscore OBIO’s continued strategic commitment to building the long-term value of this FDA Breakthrough Designation Device therapy for which it has a strategic collaboration with Medtronic. Here are what we see as the key value drivers behind today’s announcement:

1. **Reinforced Global Exclusivity**
   
   OBIO’s intellectual property spans key geographies, including the **U.S., Europe, Japan, and China**, providing a strong foundation for future commercialization and strategic partnerships.
2. **New Strategic Footing in Heart Failure, Highlighting a Market Expansion**
   
   OBIO’s also disclosed that it has secured a total of **17 issued patents** protecting AVIM therapy for the treatment of heart failure — a global disease affecting over **64 million people**. This significantly expands OBIO’s clinical footprint and future market potential.
3. **Broader FDA Recognition of AVIM’s Potential**
   
   The FDA recently granted **Breakthrough Device Designation** to AVIM therapy for **a broad patient population** that has uncontrolled hypertension and increased cardiovascular risk. This reflects growing regulatory validation of AVIM’s potential.
   
   OBIO’s mission is to bring high-impact medical innovations to patients with serious unmet needs. With a deepening IP moat, breakthrough designation status, and a pivotal global trial underway, we believe AVIM therapy continues to represent one of the most promising device-based approaches in cardiovascular medicine today.

We look forward to sharing more as our momentum continues to build.

Orchestra is just warming up. Stay tuned!

**— Team OBIO**

[View full post](https://www.orchestrabiomed.com/hub/avim-therapy-patent-portfolio-reaches-new-milestone)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Orchestra BioMed"
  },
  "dateModified" : "2025-11-11T22:01:59.840Z",
  "datePublished" : "2025-05-09T11:00:00Z",
  "headline" : "AVIM Therapy Patent Portfolio Reaches New Milestone",
  "image" : {
    "@type" : "ImageObject",
    "height" : 2160,
    "url" : "https://7401945.fs1.hubspotusercontent-na1.net/hubfs/7401945/Regulatory.png",
    "width" : 3840
  },
  "mainEntityOfPage" : "https://www.orchestrabiomed.com/hub/avim-therapy-patent-portfolio-reaches-new-milestone",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Our Content Hub"
  }
}
```